Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Based Gene Editing Therapeutic Market Report 2026

Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Based Gene Editing Therapeutic Market Overview

• Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Based Gene Editing Therapeutic market size has reached to $5.64 billion in 2025 • Expected to grow to $15.85 billion in 2030 at a compound annual growth rate (CAGR) of 23% • Growth Driver: Rising Prevalence Of Genetic And Chronic Diseases Fueling The Growth Of The Market Due To Increasing Global Disease Burden And Demand For Targeted Precision Therapies • Market Trend: Advancements In CRISPR Gene-Edited Cell Therapies For Transfusion-Dependent Beta Thalassemia • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Based Gene Editing Therapeutic Market?

Clustered regularly interspaced short palindromic repeats (CRISPR)-based gene editing therapeutics are advanced biotechnology treatments that use CRISPR gene-editing systems to modify, remove, or replace specific genetic material within cells. These therapies enable precise targeting of disease-causing genes to treat genetic disorders, cancers, and other medical conditions. They support the development of personalized and regenerative medicine approaches by improving treatment accuracy, efficiency, and therapeutic outcomes. The main editing platforms of clustered regularly interspaced short palindromic repeats (CRISPR)-based gene editing therapeutics include clustered regularly interspaced short palindromic repeats associated protein 9, base editing, prime editing, and clustered regularly interspaced short palindromic repeats associated protein 12. Clustered regularly interspaced short palindromic repeats associated protein 9 refers to a gene editing technology that enables precise modification of DNA sequences for the treatment of genetic and acquired diseases. These therapeutics target diseases including sickle cell disease and beta thalassemia, cancer immunotherapy, hereditary blindness, Duchenne muscular dystrophy, and cardiovascular disease. They are delivered through ex vivo cell engineering, in vivo, and direct injection methods, while used by end users including pharmaceutical companies, biotechnology companies, academic and research institutes, contract research organizations, and gene therapy startups.

What Is The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Based Gene Editing Therapeutic Market Growth Forecast?

The clustered regularly interspaced short palindromic repeats (CRISPR)-based gene editing therapeutic market size is expected to see exponential growth in the next few years. It will grow to $15.85 billion in 2030 at a compound annual growth rate (CAGR) of 23.0%. The growth in the forecast period can be attributed to expansion of personalized medicine and gene based therapeutics, increasing regulatory approvals for gene editing therapies, growth in clinical trials for oncology and genetic disorders, advancement in in vivo delivery technologies, rising investment in next generation genome engineering platforms. Major trends in the forecast period include rising adoption of precision gene correction therapies for rare genetic disorders, increasing clinical focus on programmable nuclease based therapeutic platforms, expansion of personalized regenerative medicine pipelines, growing use of advanced delivery vectors for targeted gene editing, increasing integration of high fidelity gene editing validation and safety screening frameworks.

Global Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Based Gene Editing Therapeutic Market Segmentation

1) By Editing Platform: Clustered Regularly Interspaced Short Palindromic Repeats Associated Protein 9; Base Editing; Prime Editing; Clustered Regularly Interspaced Short Palindromic Repeats Associated Protein 12 2) By Disease Target: Sickle Cell Disease And Beta Thalassemia; Cancer Immunotherapy; Hereditary Blindness; Duchenne Muscular Dystrophy; Cardiovascular Disease 3) By Delivery Method: Ex Vivo Cell Engineering; In Vivo; Direct Injection 4) By End User: Pharmaceutical Companies; Biotechnology Companies; Academic And Research Institutes; Contract Research Organizations; Gene Therapy Startups Subsegments: 1) By Clustered Regularly Interspaced Short Palindromic Repeats Associated Protein 9 (CRISPR-Cas9): In Vivo Clustered Regularly Interspaced Short Palindromic Repeats Associated Protein 9 Gene Editing Therapeutics; Ex Vivo Clustered Regularly Interspaced Short Palindromic Repeats Associated Protein 9 Gene Editing Therapeutics; Viral Vector Based Clustered Regularly Interspaced Short Palindromic Repeats Associated Protein 9 Therapeutics; Non Viral Delivery Clustered Regularly Interspaced Short Palindromic Repeats Associated Protein 9 Therapeutics 2) By Base Editing: Cytosine Base Editing Therapeutics; Adenine Base Editing Therapeutics; Ribonucleic Acid Guided Base Editing Therapeutics; Precision Base Editing Therapeutics 3) By Prime Editing: Deoxyribonucleic Acid Sequence Correction Prime Editing Therapeutics; Insertion And Deletion Prime Editing Therapeutics; Programmable Prime Editing Therapeutics; High Fidelity Prime Editing Therapeutics 4) By Clustered Regularly Interspaced Short Palindromic Repeats Associated Protein 12 (CRISPR-Cas12): Single Stranded Deoxyribonucleic Acid Targeting Clustered Regularly Interspaced Short Palindromic Repeats Associated Protein 12 Therapeutics; Multiplex Clustered Regularly Interspaced Short Palindromic Repeats Associated Protein 12 Gene Editing Therapeutics; High Specificity Clustered Regularly Interspaced Short Palindromic Repeats Associated Protein 12 Therapeutics; Diagnostic And Therapeutic Clustered Regularly Interspaced Short Palindromic Repeats Associated Protein 12 Platforms

What Is The Driver Of The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Based Gene Editing Therapeutic Market?

The rising prevalence of genetic and chronic diseases is expected to propel the growth of the clustered regularly interspaced short palindromic repeats (CRISPR)-based gene editing therapeutic market going forward. Genetic and chronic diseases refer to medical conditions caused by inherited genetic mutations or long-term health disorders that persist over time, such as sickle cell anemia, cystic fibrosis, diabetes, cancer, and cardiovascular diseases. The prevalence of genetic and chronic diseases is growing due to aging populations, as older individuals develop long-term health conditions such as cancer, diabetes, cardiovascular diseases, and age-related genetic disorders. CRISPR-based gene editing therapeutics treat genetic and chronic diseases by precisely modifying disease-causing genes to correct mutations and improve long-term treatment outcomes for conditions such as cancer, diabetes, cystic fibrosis and sickle cell anemia. For instance, in October 2025, according to the Cystic Fibrosis Trust, a UK-based charity dedicated to supporting people with cystic fibrosis, cystic fibrosis patient registrations increased from 11,148 in 2022 and 11,318 in 2023 to 11,381 in 2024, reflecting continued year-over-year growth. Therefore, the rising prevalence of genetic and chronic diseases is driving the growth of the clustered regularly interspaced short palindromic repeats (CRISPR)-based gene editing therapeutic industry.

Key Players In The Global Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Based Gene Editing Therapeutic Market

Major companies operating in the clustered regularly interspaced short palindromic repeats (crispr)-based gene editing therapeutic market are Novartis AG; AstraZeneca PLC; Beam Therapeutics Inc.; CRISPR Therapeutics AG; Sana Biotechnology Inc.; Wave Life Sciences Ltd.; Editas Medicine Inc.; EditCo Bio Inc.; Cellectis S.A.; Metagenomi Inc.; Arbor Biotechnologies Inc.; Intellia Therapeutics Inc.; Caribou Biosciences Inc.; Mammoth Biosciences Inc.; Korro Bio Inc.; Scribe Therapeutics Inc.; Allogene Therapeutics Inc.; Prime Medicine Inc.

Global Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Based Gene Editing Therapeutic Market Trends and Insights

Major companies operating in the clustered regularly interspaced short palindromic repeats (CRISPR)-based gene editing therapeutic market are focusing on developing innovative therapies, such as ex vivo gene-editing therapy to treat inherited genetic disorders and improve long-term patient outcomes. Ex vivo gene-editing therapy is a treatment approach in which a patient’s cells are removed from the body, genetically modified or corrected in a laboratory using gene-editing technologies such as CRISPR/Cas9, and then infused back into the patient to help treat or potentially cure diseases by addressing the underlying genetic defect. For instance, in January 2024, Vertex Pharmaceuticals, a US-based biotechnology company, received U.S. Food and Drug Administration (FDA) approval for CASGEVY (exagamglogene autotemcel [exa-cel]) for the treatment of transfusion-dependent beta thalassemia (TDT) in patients aged 12 years and older. CASGEVY is a one-time CRISPR/Cas9 gene-edited cell therapy designed to address the underlying genetic cause of TDT and reduce dependence on chronic blood transfusions. The approval followed the earlier FDA approval of CASGEVY for sickle cell disease and marked a significant advancement in the application of genome-editing therapeutics for inherited blood disorders. Additionally, Vertex established a network of authorized treatment centers across the U.S. to support the administration of CASGEVY to eligible patients requiring specialized stem cell transplantation procedures.

What Are Latest Mergers And Acquisitions In The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Based Gene Editing Therapeutic Market?

In July 2025, Eli Lilly and Company, a US-based pharmaceutical and healthcare company, acquired Verve Therapeutics Inc. for an undisclosed amount. With this acquisition, Eli Lilly and Company aimed to strengthen its cardiometabolic and genetic medicine portfolio by integrating Verve Therapeutics, Inc.’s in vivo gene-editing therapies, thereby advancing the development of one-time treatments for patients with high cardiovascular risk and chronic cholesterol-related diseases. Verve Therapeutics Inc. is a US-based biotechnology company that specializes in developing CRISPR-based gene editing therapeutics.

Regional Outlook

North America was the largest region in the clustered regularly interspaced short palindromic repeats (CRISPR)-based gene editing therapeutic market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Based Gene Editing Therapeutic Market?

The clustered regularly interspaced short palindromic repeats (CRISPR)-based gene editing therapeutic market consists of revenues earned by entities by providing services such as gene editing research, therapeutic development, clinical trial support, genomic analysis, and cell engineering services. The market value includes the value of related goods sold by the service provider or included within the service offering. The clustered regularly interspaced short palindromic repeats (CRISPR)-based gene editing therapeutic market also includes sales of guide RNA products, gene delivery vectors, engineered cells, and laboratory reagents. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Based Gene Editing Therapeutic Market Report 2026?

The clustered regularly interspaced short palindromic repeats (crispr)-based gene editing therapeutic market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the clustered regularly interspaced short palindromic repeats (crispr)-based gene editing therapeutic industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.